AHF: SCOTUS Skrmetti Ruling a ‘Triumph of Politics over Medical Science'
LOS ANGELES--(BUSINESS WIRE)-- AIDS Healthcare Foundation (AHF) issued the following statement today regarding the court's 6 to 3 ruling earlier today ruling that Tennessee's ban on gender-affirming care for transgender minors can remain in effect. (UNITED STATES v. SKRMETTI, ATTORNEY GENERAL AND REPORTER FOR TENNESSEE, ET AL.)
'The Supreme Court decision represents the triumph of politics over medical science. Unlike the Supreme Court majority, we do not believe that medical decisions best made by doctors and families should be left up to the whims of politicians and the court."
Share
A HF statement:
'The Supreme Court decision represents the triumph of politics over medical science. Unlike the Supreme Court majority, we do not believe that medical decisions best made by doctors and families should be left up to the whims of politicians whipped up by right-wing media prejudice.'
AIDS Healthcare Foundation (AHF), the world's largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 2.3 million individuals across 48 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. In January 2025, AHF received the MLK, Jr. Social Justice Award, The King Center's highest recognition for an organization leading work in the social justice arena. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Immuno Cure and PharmaJet Announce Collaboration to Advance a Novel HIV Therapeutic DNA Vaccine Using Needle-Free Technology in Humans
HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce its upcoming collaboration with PharmaJet® to evaluate the safety and immunogenicity of HIV therapeutic DNA vaccine, ICVAX, delivered via PharmaJet's innovative Tropis® needle-free injection system in a clinical study. On June 16, 2025, Immuno Cure and PharmaJet held a material transfer agreement ("MTA") signing ceremony at the BIO 2025 International Convention in Boston, USA to commemorate such collaboration. HIV/AIDS remains a critical global health challenge today, despite advances in treatment and prevention. As of 2023, over 39 million people were living with HIV, and more than 40 million deaths have occurred since the start of the epidemic in 1981. Current antiretroviral therapy ("ART") is highly effective in suppressing the virus in HIV-1 infected individuals, but it does not provide a cure. This underscores the necessity for an effective immunotherapy that can enhance the host immune response to establish a state of ART-free virological control, or a functional cure. ICVAX employs Immuno Cure's patented PD-1-Enhanced DNA Vaccine technology, which aims to achieve sustained, immune-mediated HIV-1 virological control without the need of ART. Following the successful first-in-human ICVAX Phase I clinical trial that showed exceptional safety and immunogenicity profiles, this new clinical study will explore the use of the WHO prequalified PharmaJet Tropis device for the administration of ICVAX, which allows precise intradermal delivery through its advanced needle-free technology. Tropis' global regulatory clearances and manufacturing scale reduce development risk and may improve the DNA vaccine performance and patient's clinical experience. This study will be conducted at Prince of Wales Hospital in Hong Kong SAR, led by Professor Grace LUI, Head of the Division of Infectious Diseases at the Faculty of Medicine, the Chinese University of Hong Kong ("CUHK"). This study is a collaborative effort among Immuno Cure, CUHK, and the AIDS Institute of the University of Hong Kong, and is partially supported by the funding from the Public Sector Trial Scheme of the Innovation and Technology Commission of the HKSAR Government. Professor Zhiwei CHEN, Director of the AIDS Institute of the University of Hong Kong, serves as the Project Coordinator for this funding. Dr. Xia JIN MD PhD, CEO of Immuno Cure, said "We are thrilled to partner with PharmaJet on this innovative delivery approach to HIV treatment. This collaboration not only advances needle-free vaccination solutions but also accelerates the global commercialization potential for ICVAX and the vaccine's ability to transform HIV management." Mr. Dan MALLON, Senior Vice President of Corporate Development of PharmaJet, added "We are excited to support Immuno Cure's novel HIV-1 therapeutic vaccine program with PharmaJet's patented needle-free injection technology. PharmaJet is one of the leaders in nucleic acid-based vaccine and therapeutic delivery and we are encouraged by the potential for the Tropis intradermal delivery system to make a substantial impact for HIV patients. This partnership reflects our shared commitment to advancing innovative, patient-friendly technologies that address unmet medical needs globally." Immuno Cure and PharmaJet are committed to pioneering new frontiers in vaccine delivery and enhancing patient experiences through cutting-edge technologies. About Immuno Cure Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA Vaccine, Anti-Δ42PD1 Antibody; and Vaccine Delivery platforms. To learn more about Immuno Cure, please visit: About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. To learn more about PharmaJet, please visit: Media Contact:Immuno Cure Ms. Carol CHUNG Email: carolchung@ Immuno Cure Dr. Anthony CHEUNG Email: anthonycheung@ PharmaJet Ms. Nancy LILLIE Email: PharmaJet Mr. Dan MALLON Email: View original content to download multimedia: SOURCE IMMUNO CURE HOLDING (HK) LIMITED Sign in to access your portfolio
Wall Street Journal
4 hours ago
- Wall Street Journal
Good Supreme Court Sense on Trans Hormones
It shouldn't be news that the 14th Amendment doesn't give adolescents an effective right to access transgender hormone treatments, but it's still reassuring to see the Supreme Court say so. In a 6-3 decision Wednesday, the Justices upheld a Tennessee statute, called SB1, that bans giving such prescriptions to minors. Many other states have done the same. The 14th Amendment guarantees 'equal protection of the laws,' and the Biden Administration claimed that SB1 discriminates by sex and transgender status. 'A teenager whose sex assigned at birth is male can be prescribed testosterone to conform to a male gender identity,' it argued, 'but a teenager assigned female at birth cannot.' Yet the Supreme Court now holds that the law turns on age and diagnosis, neither of which demands heightened judicial scrutiny.
Wall Street Journal
4 hours ago
- Wall Street Journal
What Would We Do Without Experts?
The question in today's headline has often been asked by this column with a sarcastic chuckle, though sometimes it's been hard to find the humor in an age afflicted by the abuse of academic credentials for political ends. It certainly wasn't funny during the Covid panic when medical authority was used by government officials to silence dissent, restrict human liberty and impose enormous and unnecessary burdens on America's children. But today one has to be feeling a little better about the ability of a free people to make democratic choices without having to bow before an ideological agenda dressed up as scientific consensus. Last December, while it remained unclear who was running the U.S. Government, the nominal Biden administration attempted one last effort to use the court system to take power over a controversial question away from voters. Specifically the government attempted to persuade the Supreme Court to block states from deciding whether sex-transition treatments can be administered to minor children. Team Biden defended such practices with a dubious appeal to expert authority, as if it was settled science that such treatments are appropriate and necessary. Thank goodness the Supreme Court didn't buy this last heaping helping of Biden-era malarkey.
